| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13D/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
As Representatives of the several Underwriters listed in Schedule 1 hereto |
| 12 Nov 2026 | 424B5 |
| 10 Nov 2026 | 424B5 |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
1 Delivering on the promise of Prime Editing Corporate Presentation November 2026 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- |
| 08 Jul 2026 |
8-K: Other Events
On July 6, 2026, Prime Medicine, Inc. (the "Company") received a final award (the "Final Award") from the arbitration tribunal (the "Tribunal") in the Company's binding arbitration proceedings with Beam Therapeutics, Inc. ("Beam") regard... |
| 08 Jun 2026 |
Form 4: Schenkein David P, Director
Granted 75,000 Stock Option (right to buy) |
| 08 Jun 2026 |
Form 4: Marrazzo Jeffrey D, Director
Granted 75,000 Stock Option (right to buy) |
| 08 Jun 2026 |
Form 4: Nelsen Robert, Director
Granted 75,000 Stock Option (right to buy) |
| 08 Jun 2026 |
Form 4: Kelly Michael Aaron, Director
Granted 75,000 Stock Option (right to buy) |
| 08 Jun 2026 |
Form 4: Foster-Cheek Kaye I, Director
Granted 75,000 Stock Option (right to buy) |
| 08 Jun 2026 |
Form 4: Chung Wendy, Director
Granted 75,000 Stock Option (right to buy) |
| 08 Jun 2026 |
Form 4: Cahill Thomas, Director
Granted 75,000 Stock Option (right to buy) |
| 08 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy sta... |
| 07 May 2026 | 10-Q |
Loading...